MARKETSPERPSLIVE79SOCIAL
RESEARCH
Cash
Browse
Live79
Portfolio
Search
Social
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

Browse
Live79
Portfolio
Search
Social
Product
Perpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatory
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

All markets
AI
Big Tech & Business
Education
Energy
Medicine
Physics & Math
Public Health
Space

Medicine

Medicine

Will the FDA approve retatrutide?

Before Jul 1, 2027
1.31x
Before Jan 1, 2027
6.29x
$16,561 vol5 markets
Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before November
1.93x
Before 2027
1.62x
$52,557 vol3 markets
Industries

FDA decision: Gedatolisib by Celcuity Inc. (July 2026)

Full Approval
1.19x
Denied (CRL Issued)
9.41x
$6,167 vol5 markets
Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes
2.24x
No
1.57x
$9,160 vol1 market
Industries

FDA decision: Zidesamtinib by Nuvalent (this year)

Yes
1.25x
No
3.40x
$50 vol1 market
Industries

FDA decision: Venglustat by Sanofi (this year)

Yes
1.15x
No
4.31x
$0 vol1 market
Industries

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.31x
No
2.89x
$0 vol1 market
Industries

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes
1.09x
No
5.90x
$64 vol1 market
Medicine

When will Intellia Therapeutics submit a BLA for Lonvo-z?

before October
1.65x
before November
1.42x
$4,246 vol6 markets
Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before October
2.29x
before November
1.36x
$11,635 vol6 markets
Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

before December
1.62x
before November
2.29x
$3,151 vol6 markets
Industries

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.57x
No
2.14x
$115 vol1 market
Industries

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.22x
No
3.66x
$30 vol1 market
Industries

FDA decision: Iberdomide by Celgene (this year)

Yes
1.40x
No
2.59x
$13 vol1 market
Medicine

Will the FDA approve VERVE-102?

Before 2030
1.67x
Before 2031
1.44x
$1,386 vol6 markets
Medicine

Will the FDA approve camizestrant for advanced breast cancer?

Before Jan 1, 2027
1.52x
Before Oct 1, 2026
2.66x
$8,891 vol3 markets
Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before October 2027
1.79x
Before 2028
1.42x
$2,786 vol3 markets
Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Mar 1, 2027
1.90x
Before Jan 1, 2027
2.81x
$12,767 vol5 markets
Industries

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

Yes
1.44x
No
2.52x
$90 vol1 market
Industries

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes
1.22x
No
3.66x
$47 vol1 market
Industries

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes
1.05x
No
8.56x
$11 vol1 market
Industries

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.29x
No
3.08x
$64 vol1 market
Industries

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.06x
No
7.85x
$18 vol1 market
Industries

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.23x
No
3.66x
$458 vol1 market